Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04, FiscalAI reports.
Kairos Pharma Stock Down 5.6%
Shares of Kairos Pharma stock traded down $0.03 during trading hours on Friday, reaching $0.45. 12,561 shares of the stock traded hands, compared to its average volume of 91,918. Kairos Pharma has a one year low of $0.42 and a one year high of $7.28. The firm has a market capitalization of $1.54 million, a price-to-earnings ratio of -0.23 and a beta of 1.85. The company has a 50 day moving average price of $1.08 and a 200 day moving average price of $2.80.
Kairos Pharma Company Profile
Kairos Pharma, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies designed to address immune suppression and treatment resistance within the tumor microenvironment. The company’s research is centered on immuno-oncology approaches intended to improve the body’s ability to recognize and attack cancer cells. Kairos Pharma is developing a pipeline of investigational therapies, including antibody-based and small-molecule programs aimed at biological pathways associated with tumor growth, immune evasion and resistance to existing treatments.
Read More
- Five stocks we like better than Kairos Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
